Clinical Research Directory

Inclusion Criteria * Age ≥ 18 years. * Clinical diagnosis of retinitis pigmentosa (RP) or EMAP (Extensive Macular Atrophy with Pseudodrusen-like Appearance), confirmed by multimodal evaluation. * Best-corrected visual acuity (BCVA) ≥ counting fingers at 1 meter (approximately ≤ 1.9 logMAR) in the study eye. * Measurable visual field on iCare COMPASS (10-2 or 24-2) with acceptable reliability indices. * Clear ocular media adequate for safe intravitreal injection and high-quality optical coherence tomography (OCT) imaging. * Ability and willingness to provide written informed consent. * Ability to comply with scheduled study visits, including: * Baseline (M0) * Day 7-14 after injections * Month 2 (M2), Day 7-14 * Month 4 (M4), Day 7-14 * Month 6 (M6) * For ERG subset only: o Presence of a recordable baseline 30-Hz flicker electroretinogram (ERG) response, defined as a signal-to-noise ratio ≥ 3:1 and amplitude ≥ 3.0 μV. * Note: Absence of a measurable flicker ERG response does not exclude participation in the main study. Exclusion Criteria * Active ocular inflammation (anterior, intermediate, or posterior uveitis) or active infectious ocular disease in the study eye. * Active choroidal neovascularization or other macular diseases unrelated to RP or EMAP. * Uncontrolled glaucoma (intraocular pressure \> 21 mmHg despite therapy) or optic neuropathies not related to RP or EMAP. * Significant media opacity that may impair imaging quality or compromise the safety of intravitreal injection. * Recent ocular interventions that may confound study outcomes, including: * Intravitreal therapy within 3 months prior to enrollment. * Periocular corticosteroid injection within 3 months prior to enrollment. * Major intraocular surgery within 3 months prior to enrollment. * Known hypersensitivity to adalimumab, povidone-iodine, local anesthetics, or any component of the study formulations. * Coagulopathy or contraindications to ocular injections, including: * Platelet count \< 100,000/μL, or * INR \> 1.5 unless adequately corrected. * Pregnancy or breastfeeding. * Women of childbearing potential unwilling to use effective contraception during the study period. * Uncontrolled systemic disease that, in the investigator's judgment, increases risk or interferes with study participation or completion. * Participation in another interventional clinical trial within 3 months prior to enrollment.